

From: s 47F
To: [SCHOFIELD, Lisa](#)
Cc: s 22 s 22 s 22
Subject: RE: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=OFFICIAL]
Date: Thursday, 23 July 2020 10:30:50 AM
Attachments: [image001.png](#)
[image002.png](#)

REMINDER : Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Hi Lisa

I just wanted to give you a heads up that Pfizer has been approached by trade media with an enquiry regarding engagement with Government on COVID vaccine procurement and manufacturing.

In response we have provided the following statement attributable to a spokesperson for Pfizer:

“Pfizer is committed to bringing this vaccine to all who need it to help meet the global public health need. Should our vaccine be successful in clinical trials and receive regulatory approval, we will work closely with governments, and other vaccine manufacturers to supply the world as quickly as we can, together. Discussions with government remain confidential.”

Please let me know if you have any queries on this.

Also, I assume you have seen the recent news of Pfizer’s agreements with the [UK](#) and [US](#) on vaccine supply. It seems that both our legal representatives are close to resolving the few outstanding issues with the CDA. I look forward to scheduling another meeting with you to progress our discussions once this is signed.

Kind regards

s 47F

From: Schofield, Lisa <Lisa.Schofield@health.gov.au>

Sent: Wednesday, 8 July 2020 9:44 AM

To: s 47F

Cc: s 22

Subject: [EXTERNAL] RE: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=OFFICIAL]

Hi s 47F

We are considering the CDA. It is not usual practice for the Commonwealth to sign such documents as we are covered by various legislative requirements to keep information gained through our employment confidential.

I would like to propose that we keep the slot on Friday morning and have the introductory/exploratory discussion you suggest. We can always line up subsequent ones as needed.

Cheers
Lisa

From: s 47F
Sent: Tuesday, 7 July 2020 6:05 PM
To: Schofield, Lisa <Lisa.Schofield@health.gov.au>
Cc: s 22

Subject: RE: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=OFFICIAL]

Hi Lisa

Following up on the below, plus I have some extra information to add.

Once the CDA is signed, we have a lengthy and highly detailed slide deck to run through with you. This goes through the scientific development and clinical trial process underway, medical information on the novel RNA vaccine technology, manufacturing, supply chain and procurement processes.

As a result the strong recommendation is for a 90 minute meeting to have sufficient time to get through all of this detail and Q&A.

Also, we are unable to provide copies of the slide deck so it must be shared through screen-sharing via a video-conferencing link. As mentioned below, I am happy to set that up through WebEx which is our preferred platform.

Please let me know how you would like to proceed. I am on leave tomorrow but will be back on deck on Thursday morning. I am assuming a postponement to next week to enable time to review and sign the CDA, and find an appropriate time slot, is most likely but my local colleagues are keeping 10.30am on Friday free nonetheless.

I have cc'd s 22, with whom I spoke yesterday as she expressed interest to join the call, which is of course fine with us.

Thanks and I look forward to hearing from you.

Kind regards

s 47F

From: s 47F
Sent: Monday, 6 July 2020 5:45 PM
To: Schofield, Lisa <Lisa.Schofield@health.gov.au>
Cc: s 22
Subject: RE: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=OFFICIAL]

Hi Lisa

Thanks for your assistance in organising a (virtual) meeting with you on Friday to discuss Pfizer's approach to COVID-19 vaccine development and distribution (in partnership with BioNTech).

I have just received guidance from my colleagues in Europe managing this project that in order to provide any level of detail on Pfizer's approach we will need to have a Confidential Disclosure Agreement signed by both parties prior to the meeting. Attached is the CDA which our Global

Head of Vaccines is ready to sign should it meet your approval.

If we can get this signed ahead of Friday's meeting then we will include several senior Global Pfizer colleagues on the call to be able to provide the detail you may be seeking on a range of issues. However as these colleagues are all based in Europe I will need to request a time change, to be a bit more suitable to all participants (10.30am here is 1.30am in London). Our 4.00pm, or any time after that, usually works best.

Alternatively we are happy to treat this Friday as just an exploratory / introductory meeting without the CDA, in which case it will be limited to my Australian colleagues (including the Managing Director of Pfizer Australia & NZ).

Your guidance on this will be appreciated.

On a separate issue, I note s 22 has included tele-conference dial-in details. We are happy to do this by video-conference to improve the engagement. I can circulate a WebEx link if you are agreeable.

Thanks for your consideration of these matters.

Kind regards

s 47F

From: Schofield, Lisa <Lisa.Schofield@health.gov.au>

Sent: Friday, 3 July 2020 8:34 AM

To: s 47F

Cc: s 22

Subject: [EXTERNAL] RE: Letter to Minister Hunt re Pfizer vaccine development for COVID-19.
[SEC=OFFICIAL]

Hi s 47F

s 22 passed on your email and letter to Minister Hunt.

I am managing the whole of government work on COVID-19 vaccine from the Department of Health.

I would very much appreciate an opportunity to talk to Pfizer about your vaccine work – both the development and manufacturing activities and plans.

I'll ask my EA, s 22, to get in touch with you and arrange a suitable time.

Cheers

Lisa

Lisa Schofield

First Assistant Secretary, Health Economics and Research Division
Australian Government Department of Health

P: 02 6289 7480 | s 22

E: lisa.schofield@health.gov.au

I acknowledge the traditional custodians of the lands and waters where we live and work, and pay my respects to elders past, present and future.

s 22

From: s 47F

Sent: Tuesday, 30 June 2020 4:38 PM

To: s 22

Cc: s 47F

Subject: Letter to Minister Hunt re Pfizer vaccine development for COVID-19. [SEC=No Protective Marking]

Hi s 22

It was really good to catch up last Friday. Thanks for all your time.

As discussed, please find attached a letter from Pfizer Australia MD s 47F with some information about Pfizer's vaccine development in response to COVID-19.

This includes a request for a formal (virtual) engagement opportunity with members of the Vaccines Taskforce to be selected at your discretion. I am able to make senior members of Pfizer's global leadership team available for this discussion, particularly if the Minister and/or Departmental leadership can be involved. As the vaccine development landscape is moving swiftly, including through engagements with other nations, I am requesting this meeting occur at the earliest opportunity.

I am happy to discuss this matter further at any time.

Kind regards

s 47F

Pfizer Australia

s 47F

www.pfizer.com.au

Level 3, 500 Collins Street

Melbourne, VIC, 3000

s 47F



LEGAL NOTICE Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee(s) only. Access to this e-mail by anyone else is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you are not an addressee, please inform the sender immediately. Pfizer Australia has its registered office at Level 15-18, 151 Clarence Street, Sydney, NSW, 2000

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982 (CTH)
BY THE DEPARTMENT OF HEALTH